Sanofi Basic Shares Outstanding 2010-2024 | SNY
Sanofi annual/quarterly basic shares outstanding history and growth rate from 2010 to 2024. Basic shares outstanding can be defined as the number of shares held by shareholders including insiders but not including a company's treasury shares.
- Sanofi basic shares outstanding for the quarter ending September 30, 2024 were $2.506B, a 0.02% decline year-over-year.
- Sanofi basic shares outstanding for the twelve months ending September 30, 2024 were $10.007B, a 0.03% decline year-over-year.
- Sanofi annual basic shares outstanding for 2023 were $2.503B, a 0.02% decline from 2022.
- Sanofi annual basic shares outstanding for 2022 were $2.504B, a 0.05% decline from 2021.
- Sanofi annual basic shares outstanding for 2021 were $2.505B, a 0.09% decline from 2020.
Sanofi Annual Basic Shares Outstanding
(Millions of US $) |
| 2023 |
$2,503 |
| 2022 |
$2,504 |
| 2021 |
$2,505 |
| 2020 |
$2,507 |
| 2019 |
$2,500 |
| 2018 |
$2,494 |
| 2017 |
$2,514 |
| 2016 |
$2,573 |
| 2015 |
$2,612 |
| 2014 |
$2,632 |
| 2013 |
$2,646 |
| 2012 |
$2,642 |
| 2011 |
$2,643 |
| 2010 |
$2,611 |
| 2009 |
$2,612 |
Sanofi Quarterly Basic Shares Outstanding
(Millions of US $) |
| 2024-09-30 |
$2,506 |
| 2024-06-30 |
$2,500 |
| 2024-03-31 |
$2,498 |
| 2023-12-31 |
$2,503 |
| 2023-09-30 |
$2,506 |
| 2023-06-30 |
$2,501 |
| 2023-03-31 |
$2,499 |
| 2022-12-31 |
$2,504 |
| 2022-09-30 |
$2,507 |
| 2022-06-30 |
$2,502 |
| 2022-03-31 |
$2,498 |
| 2021-09-30 |
$2,509 |
| 2021-06-30 |
|
| 2021-03-31 |
$2,499 |
| 2020-09-30 |
$2,511 |
| 2020-03-31 |
$2,503 |
| 2019-09-30 |
$2,504 |
| 2019-03-31 |
$2,498 |
| 2018-03-31 |
$2,496 |
| 2017-12-31 |
$2,514 |
| 2017-09-30 |
$2,509 |
| 2017-06-30 |
$2,516 |
| 2017-03-31 |
$2,525 |
| 2016-12-31 |
$2,573 |
| 2016-09-30 |
$2,577 |
| 2016-06-30 |
$2,574 |
| 2016-03-31 |
$2,577 |
| 2015-09-30 |
$2,611 |
| 2015-06-30 |
$2,612 |
| 2014-06-30 |
$2,634 |
| 2013-06-30 |
$2,691 |
| 2012-06-30 |
$2,631 |
| 2012-03-31 |
$2,642 |
| 2011-12-31 |
$2,660 |
| 2011-09-30 |
$2,678 |
| 2011-06-30 |
$2,588 |
| 2011-03-31 |
$2,614 |
| 2010-12-31 |
$2,610 |
| 2010-09-30 |
$2,610 |
| 2010-06-30 |
$2,606 |
| 2010-03-31 |
$2,609 |
| 2009-12-31 |
$2,614 |
| 2009-09-30 |
$2,611 |
| 2009-06-30 |
$2,611 |
| 2009-03-31 |
$2,609 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$122.704B |
$46.611B |
|
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
|
